Phase II Randomised Clinical Trial Evaluating an EGFR Tyrosine Kinase Inhibitor (EGFR-TKI) Versus an EGFR-TKI Combined With an Anti-oestrogen Treatment (Fulvestrant) in Women With Advanced Stage Non-squamous Lung Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 05 Jun 2018
At a glance
- Drugs Fulvestrant (Primary) ; Erlotinib; Gefitinib
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms LADIE
- 05 Jun 2018 Results (n=204) presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
- 19 Sep 2017 Planned primary completion date changed from 1 May 2017 to 1 Mar 2018.
- 19 Sep 2017 Status changed from recruiting to active, no longer recruiting.